Table 7.
Antiviral agents targeting EBV lytic cycle in EBV-related diseases
| Agents | Mechanism | Model | Reference |
|---|---|---|---|
| Valproic acid | Inhibits Zta and Rta expression | In vitro (Burkitt’s lymphoma) | 248 |
| Valpromide | Inhibits Zta and Rta expression | In vitro (Burkitt’s lymphoma) | 249 |
| Maribavir | Inhibiting the enzymatic activity of EBV-PK | In vitro (Burkitt’s lymphoma) | 252,253 |
| Spironolactone | Inhibits SM expression | In vitro (Burkitt’s lymphoma, GC) | 250 |
| Dnazyme | Inhibits LMP1 expression | In vivo (NPC) | 254,255 |
| Epigallocatechin gallate | Inhibits EBV lytic gene expression | In vitro (Burkitt’s lymphoma, NPC) | 258,264,265 |
| Curcumin | Inhibits BZLF1 gene transcription | In vitro (Burkitt’s lymphoma) | 256 |
| Sulforaphane | Reduces the transactivation activity of the BRLF1 gene | In vitro (NPC) | 257 |
| Protoapigenone | Reduces the transcriptional function of Zta | In vitro (Burkitt’s lymphoma) | 259 |
| Moronic acid | Suppresses the transactivation function of Rta | In vitro (Burkitt’s lymphoma) | 260 |
| Emodin | Inhibits EBV IE protein expression and DNA replication | In vitro (Burkitt’s lymphoma) | 261 |
| Glycyrrhizic acid | Inhibits EBV IE protein expression and DNA replication | In vitro (Burkitt’s lymphoma) | 262 |
| Vitamin C | Reduces EBV EA IgG and VCA IgM antibody levels | In vivo (CAEBV) | 263 |